AUTHORS
Ting Cao, PhD, Xilin Chen, PhD2, Yanchen Li, MSc3, Yi Ma4, Xiubin Xiao5, Tonghui Ma6, Wenrong Huang, Professor/Chief Physician7
AFFILIATIONS
1 Genetron Health (Beijing) Co. Ltd.,, Beijing, China
2 The Fifth Medical Center of the Chinese People's Liberation Army General Hospital, Beijing, China
3 Genetron Health (Beijing) Co. Ltd.,, Beijing, China
4 The Fifth Medical Center of the Chinese People's Liberation Army General Hospital, Beijing, China
5 The Fifth Medical Center of the Chinese People's Liberation Army General Hospital, Beijing, China
6 Genetron Health (Beijing) Co. Ltd.,, Beijing, China
7 The Fifth Medical Center of the Chinese People's Liberation Army General Hospital, Beijing, China
ABSTRACT
Introduction: Bone marrow (BM) remains the reference specimen for measurable residual disease (MRD) assessment in multiple myeloma (MM). However, baseline clonotype identification fails in 15-20% of patients, predominantly because of lower tumor-cell content and yields ambiguous polyclonal repertoires. Blood-based MRD testing offers a less invasive alternative; however, the optimal peripheral blood specimen for V(D)J clonotype identification and longitudinal MRD monitoring has not been established. We systematically compared paired BM, plasma cell-free DNA (cfDNA), and peripheral blood leukocytes to determine the most informative peripheral specimen for V(D)J-based clonotype detection and to evaluate the feasibility of plasma cfDNA for serial MRD assessment.
Methods: Thirty newly diagnosed, treatment-naïve MM patients were prospectively enrolled with paired BM aspirates, plasma cfDNA, and PB leukocytes collected at diagnosis. All three specimen types underwent a standardized high-throughput V(D)J sequencing assay (Seq-MRD®, Genetron Health) for baseline clonotype identification. Post-treatment MRD was assessed in eight paired BM and plasma cfDNA samples, with BM multiparameter flow cytometry (MFC) as the clinical reference. Cross-specimen quantitative agreement was evaluated by correlation and Cohen's kappa. Two patients underwent longitudinal plasma cfDNA MRD monitoring during sequential anti-myeloma therapy.
Results: At baseline, plasma cfDNA identified the same dominant clonotype as BM in 24 of 30 patients (80%). In one additional patient with inconclusive BM clonotyping caused by an ambiguous polyclonal repertoire, plasma cfDNA successfully identified a dominant tumor-specific clonotype, demonstrating its complementary diagnostic value. In contrast, peripheral blood leukocyte sequencing consistently showed polyclonal immune repertoires without detectable dominant malignant clonotypes in all 30 patients, indicating that leukocyte-derived DNA is not an appropriate substrate for V(D)J clonotype identification in MM.
Among the eight patients with paired post-treatment samples, plasma cfDNA MRD levels demonstrated a strong correlation with BM MRD quantified by V(D)J sequencing (r = 0.78). All BM MRD-negative cases were concordantly negative in plasma cfDNA, while plasma cfDNA also showed acceptable concordance in MRD-positive cases across different disease burdens. In two patients with serial follow-up, plasma cfDNA MRD levels progressively declined during treatment and closely paralleled clinical response, supporting its utility for non-invasive longitudinal disease monitoring.
Conclusions: Our findings demonstrate that plasma cfDNA, but not peripheral blood leukocytes, provides a biologically informative and clinically applicable peripheral specimen for V(D)J clonotype identification in multiple myeloma. Plasma cfDNA showed high concordance with bone marrow for baseline clonotype detection and accurately reflected longitudinal MRD dynamics during treatment, supporting its use as the preferred peripheral specimen for blood-based V(D)J MRD assays. Larger prospective studies with long-term clinical follow-up are warranted to further define its prognostic value and its role in complementing bone marrow-based MRD assessment.
DISCLOSURES
Ting Cao, PhD: No relevant conflicts of interest to declare.